Adjunctive therapy to diet to reduce elevated total cholesterol (total-C), LDL, apolipoprotein B (ApoB), non-HDL, and TG levels, and to increase HDL in adults with primary hyperlipidemia or mixed dyslipidemia; to reduce total-C, LDL, and ApoB levels in adolescents who are at least 1 yr postmenarche (females), 10-17 yrs of age with heterozygous familial hypercholesterolemia (HeFH) and who if after diet therapy present with LDL >190mg/dL or >160mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or ≥2 other CVD risk factors; for the treatment of hypertriglyceridemia in adults; for the treatment of primary dysbetalipoproteinemia (Type III hyperlipoproteinemia); to slow the progression of atherosclerosis in adults as part of a treatment strategy to lower total-C and LDL to target levels. Adjunctive therapy to other lipid-lowering treatments (eg, LDL apheresis), or alone if such treatments are unavailable to reduce LDL, total-C, and ApoB in adults with homozygous familial hypercholesterolemia (HoFH). Reduces risk of myocardial infarction, stroke, and arterial revascularization procedures in individuals with an increased risk of CVD.
